Benign prostatic hyperplasia (BPH) can enlarge the prostate and obstruct urinary flow. Avodart contains dutasteride, a dual 5-alpha-reductase inhibitor for men with moderate to severe BPH. It gradually reduces dihydrotestosterone activity, helping shrink prostate tissue and improve lower urinary tract symptoms.
Avodart is an oral urology treatment containing dutasteride in soft capsules. It is classified as a dual 5-alpha-reductase enzyme inhibitor and is prescribed for adult men with moderate to severe benign prostatic hyperplasia (BPH). The amount per intake is set individually for each person rather than being one fixed number.
The main clinical applications include:
Avodart does not work by relaxing the prostate immediately. Its benefit develops through gradual hormonal suppression and tissue changes. Men with a very large prostate may gain more from a prostate-shrinking treatment than from an alpha-blocker alone, while symptom severity, urinary flow, bladder function, and PSA results also influence treatment selection.
The European Medicines Agency describes dutasteride as a treatment for moderate to severe BPH and confirms its role in reducing prostate-related obstruction [1].
Dutasteride inhibits both type 1 and type 2 5-alpha-reductase enzymes, reducing the conversion of testosterone to dihydrotestosterone. Lower dihydrotestosterone activity reduces androgen stimulation in prostate tissue, allowing the enlarged prostate to gradually shrink. This can relieve obstruction and improve urinary flow and lower urinary tract symptoms.
This medicine is not for you if:
Avodart is intended for adult men with BPH. Women must not take dutasteride, and pregnant women or women who could become pregnant should not handle leaking soft capsules.
Dutasteride has antiandrogenic properties. A male fetus exposed during development could experience impaired formation of the external genitalia. The risk explains the strict handling precautions and the prohibition on use during pregnancy.
Breastfeeding is not a routine indication for Avodart, and women who are breastfeeding should not take it. Children and adolescents must not use dutasteride because its safety and clinical role differ from adult BPH treatment.
Avodart is generally tolerated by many men, but dutasteride can cause adverse reactions. The main reported effects involve sexual function, breast tissue, and reproductive parameters.
Common or clinically recognised reactions include:
Sexual adverse effects may appear during the early months of therapy and may improve with continued treatment. They can also persist after discontinuation in some men, although the frequency and causal relationship remain difficult to establish for every individual. The Avodart Summary of Product Characteristics lists impotence, altered libido, ejaculation disorders, and breast symptoms among recognised adverse reactions [2].
Sexual symptoms deserve a direct conversation before treatment begins. A man who already has erectile dysfunction, low libido, infertility concerns, or depression may need a different risk-benefit discussion than a man without those issues.
Breast enlargement is uncommon but should not be ignored. Report a breast lump, nipple discharge, or persistent breast pain promptly because these symptoms require clinical assessment.
Allergic reactions are uncommon. Facial swelling, difficulty breathing, widespread blistering, or severe skin peeling requires urgent medical attention.
One practical detail is easy to overlook: sexual adverse effects can be caused by BPH itself, age-related vascular disease, diabetes, depression, or another medicine. A change after starting Avodart is relevant, but it does not automatically prove that dutasteride is the only cause.
Avodart contains the active ingredient dutasteride in soft capsules. Dutasteride is a dual 5-alpha-reductase inhibitor that reduces dihydrotestosterone activity and supports gradual reduction of prostate tissue.
| Treatment | Main pharmacological role | Usual clinical profile |
|---|---|---|
| Dutasteride | Blocks type 1 and type 2 5-alpha-reductase | Gradually reduces prostate volume and DHT activity |
| Finasteride | Mainly blocks type 2 5-alpha-reductase | Shrinks the prostate gradually in suitable men |
| Alpha-blocker such as tamsulosin | Relaxes smooth muscle around the prostate and bladder neck | Often improves urinary flow sooner, without shrinking the prostate |
Dutasteride inhibits both major 5-alpha-reductase isoenzymes. Finasteride has a more selective type 2 effect. Both treatments require continued use and are more useful when prostate enlargement contributes significantly to obstruction.
Dutasteride may produce broader DHT suppression, while finasteride may have a shorter persistence after discontinuation. Neither treatment should be judged after only a few days. Their main limitations are delayed symptom improvement and possible sexual adverse effects.
The name Propecia is associated with finasteride used for hair loss, while finasteride is also used in a different strength for BPH. The indication and strength matter. A finasteride product for hair loss is not an automatic substitute for a BPH regimen.
An alpha-blocker such as tamsulosin relaxes smooth muscle and may improve urinary symptoms sooner. It does not reduce prostate volume. Dutasteride addresses prostate growth but usually takes longer to produce noticeable symptom relief.
For men with moderate to severe symptoms and a larger prostate, a clinician may consider dutasteride with an alpha-blocker. The combination can pair rapid smooth-muscle relaxation with gradual prostate shrinkage, though dizziness, low blood pressure, ejaculation problems, and other adverse effects may become more relevant.
The choice should reflect the person’s blood pressure, fall risk, sexual priorities, prostate size, and expected duration of treatment. The American Urological Association guideline supports using 5-alpha-reductase inhibitors for suitable men with demonstrable prostate enlargement [3].
Several practical errors reduce the value of treatment:
If a dose is missed, the usual approach is to take it when remembered unless the next scheduled dose is near. Taking two capsules together is not a substitute for the missed dose. A sudden inability to pass urine, severe lower abdominal pain, fever, or visible blood in urine requires prompt medical assessment.
In clinical practice, doctors usually set expectations around time. Dutasteride can lower DHT before a patient feels urinary improvement, so an early lack of symptom change does not necessarily mean treatment has failed.
A clinician will also monitor the reason for treatment rather than relying on symptoms alone. PSA interpretation, prostate size, urinary flow, bladder emptying, recurrent infections, and episodes of retention can all change the management plan.
A urologist may say, “The capsule treats the prostate-growth pathway, not every cause of urinary frequency.” Night-time urination can also arise from excessive evening fluids, sleep apnoea, diabetes, ankle swelling, or bladder overactivity.
Long-term treatment may be appropriate for men who benefit and tolerate it. Follow-up remains useful because urinary obstruction can progress even when symptoms seem stable.
Avodart can generally be taken once daily at a consistent time, with or without food. The exact amount per intake is individualised rather than being one fixed number for every person. NHS medicine guidance reviewed in 2025 supports using a regular routine to reduce missed doses and maintain continuity. A clinician can align the schedule with other medicines. Follow-up should account for symptom response and adverse effects.
Avodart is not suitable for women, pregnancy, or breastfeeding. Dutasteride can affect development of the external genitalia in a male fetus, which is why pregnant women must avoid contact with leaking capsules. MHRA safety information available in 2025 continues to describe these reproductive precautions.
Take the missed capsule when remembered unless it is nearly time for the next one. Do not take two capsules together to compensate. The EMA product information reviewed in 2024 advises avoiding double dosing after a missed dose.
Avodart is often used for months or longer when BPH remains clinically significant and the treatment is tolerated. The amount per intake is set individually, while duration depends on symptoms, prostate findings, PSA monitoring, and treatment response. NICE guidance active in 2025 supports ongoing review of long-term medicines used for lower urinary tract symptoms.
Some hormonal changes begin early, but urinary improvement usually develops gradually because prostate tissue needs time to shrink. A noticeable benefit may take several months, and some men need combination treatment for symptom control. EMA clinical information from 2024 describes the delayed therapeutic profile of dutasteride compared with medicines that relax smooth muscle.
Older men may use Avodart when BPH and prostate enlargement make a 5-alpha-reductase inhibitor suitable. Age alone does not determine eligibility, but falls, dizziness, sexual health, liver function, and multiple medicines require attention. WHO healthy-ageing guidance published in 2024 supports individual review of polypharmacy and treatment-related functional risks.
Dutasteride may be prescribed with an alpha-blocker such as tamsulosin in men with moderate to severe BPH. This can improve symptoms through two different mechanisms, while dizziness, low blood pressure, and ejaculation disorders may become more relevant. The European Association of Urology guideline updated in 2025 supports mechanism-based combination treatment for selected men with bothersome lower urinary tract symptoms.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took Avodart 0.5 mg daily for several months and gradually noticed that getting started was easier and the stream was stronger. Night-time trips became less disruptive, so I felt the treatment was worthwhile.
After taking Avodart 0.5 mg daily for several months, I found that urgency was less troublesome during work. The improvement was gradual rather than sudden, but my routine became easier.
I took Avodart 0.5 mg daily for several months but did not notice enough urinary improvement to feel the treatment was helping. My sexual function also became a concern, so I stopped and discussed other options with my doctor.
After taking Avodart 0.5 mg daily for several months, the main change was fewer interruptions at night. It took patience, but after continued treatment I was sleeping more consistently and felt more comfortable during the day.
After taking Avodart 0.5 mg daily for several months, the urinary symptoms improved partly, though not as much as I hoped. I also noticed lower interest in sex for a period, so I spoke with my doctor about whether the benefit justified continuing.
